Navigation Links
NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma

Program Seeks to Identify microRNA Biomarkers for Overall Survival and Risk

of Melanoma Metastasizing to Distant Sites

REHOVOT, Israel and NEW YORK, September 7 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a global leader in the field of microRNA and RNAi, announced today it will be working in collaboration with NYU Medical Center to leverage the significant potential of microRNA profiles to develop a diagnostic test for melanoma.

Rosetta Genomics believes its unique diagnostic engine has enabled it to discover the majority of known microRNA sequences for which it has submitted a series of patent applications. With this proprietary engine, Rosetta will screen more than 700 microRNAs (many of which are not publicly available) in order to identify the right signature which will potentially be able to quickly and efficiently find the right prognostic indicator test for harmful melanomas.

While this melanoma diagnostic test is still in the early stages, Rosetta Genomics plans to launch three diagnostic products in 2008 that include a test for cancer of unknown primary ("CUP") and two differential diagnostic tests related to lung cancer. The company will continue gradually to expand its pipeline with more diagnostic and eventually therapeutic applications.

"We see helping cure cancer as an incredibly important responsibility for Rosetta Genomics. Much of our work surrounds discovering microRNA biomarkers, and given how much is known about the connection between microRNA and cancer, we believe that we are in a unique position to advance the fields of cancer diagnosis, prognosis and therapeutics. This collaboration with NYU will give both organizations an opportunity to understand a deadly cancer in new ways and to try to save patient lives," said Amir Avniel, Rosetta Genomics' Chief Executive Officer.

Melanoma is one of the leading causes of skin cancer deaths, accounting for 48,000 fatalities worldwide each year. It is one of the more rare types of skin cancer but causes the majority of skin cancer related deaths. This collaboration seeks to identify microRNAs that can be used as prognostic indicators for the overall survival of melanoma patients and the risk that the disease will metastasize to distant sites.

"Each year more than 150,000 people are diagnosed with melanoma," said Dr. Eva Hernando of the Department of Pathology at the NYU School of Medicine. "We believe that through our work with microRNAs, which have been shown to hold tremendous potential as biomarkers, we will be able to better understand both the origins and the development of the disease. NYU's extensive experience with melanoma, combined with Rosetta Genomics unmatched knowledge in microRNAs offers an exciting research opportunity."

"We see microRNAs as the biomarkers of the future," said Dr. Dalia Cohen, Executive Vice President, Global Research and Development of Rosetta Genomics. "There is a large and growing body of scientific evidence pointing to microRNAs' potential as diagnostic and prognostic biomarkers for various types of cancers. We believe our work with world renowned experts in melanoma such as Dr. Nina Bhardwaj at NYU, and deploying the proprietary tools developed at Rosetta Genomics for microRNA extraction, identification and quantification, will help to more fully understand melanoma and subsequently the prognosis of melanoma patients."

About microRNAs

MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.

About NYU Medical Center

One of the world's premier academic medical institutions for more than 155 years, NYU Medical Center continues to be a leader in patient care, physician education and scientific research. NYU Medical Center is internationally renowned for excellence in areas such as cardiovascular disease, pediatrics, skin care, neurosurgery, urology, cancer care, rehabilitation, plastic surgery, minimally invasive surgery, transplant surgery, infertility, women's health and day surgery.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA and RNAi. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and other diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to our ability to successfully develop early detection diagnostic products for lung cancer and Melanoma in collaboration with NYU Medical Center, the role of miRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of Rosetta's product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's most recent Registration Statement on Form F-1 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media

Alan Zachary

T: +1-312-944-6784


Juliane Snowden

T: +1-212-213-0006

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
Breaking Biology Technology:
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
Breaking Biology News(10 mins):